There is no consensus on the importance of visit-to-visit glycemic variability in diabetes. Therefore, we assessed the effects of visit-to-visit variability (VVV) in HbA 1c and fasting glucose on major outcomes in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) trial.
Diabetes is an important cause of mortality and morbidity worldwide, through both direct clinical sequelae and increased mortality from cardiovascular and kidney diseases (1) . Due to population aging and increasing obesity, diabetes is expected to rise globally from 152 million in 1980 to 552 million in 2030 (2, 3) . Effective prevention of diabetesrelated premature death and morbidity requires better management and control of diabetes and other cardiovascular risk factors.
In the management of diabetes, underlying usual levels of HbA 1c and blood glucose (conceived as the true underlying average levels over a period of time) are widely considered to be of primary importance. Recently, a number of studies have raised concerns about possible adverse effects of visit-to-visit glycemic variability in diabetes (4) (5) (6) (7) (8) (9) (10) (11) (12) . Therefore, glycemic variability has the potential to provide additional value in the prediction of future complications in diabetes. However, current evidence of the effect of visit-to-visit glycemic variability is insubstantial for macrovascular events in type 2 diabetes and is controversial in type 1 diabetes (13) . There have also been several reports on the importance of variability from hour to hour, within a single day, or between days, which may reflect the influence of a variety of different mechanisms, but such short-term effects are not considered in this article (14) (15) (16) (17) (18) .
The purpose of this study was to investigate the association of visit-to-visit variability (VVV) in HbA 1c and fasting glucose with the risks of microvascular events, macrovascular events, and allcause mortality among patients with type 2 diabetes using data from the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) trial.
RESEARCH DESIGN AND METHODS

Study Design
ADVANCE was a factorial randomized controlled trial of blood pressure lowering and intensive blood glucose treatment in patients with type 2 diabetes. The design has been described in detail previously (19, 20) . In brief, a total of 11,140 patients with type 2 diabetes aged 55 years or older who had a history of major macrovascular or microvascular disease, or at least one other risk factor for vascular disease, were recruited from 215 collaborating centers in 20 countries from Asia, Australasia, Europe, and North America between November 2001 and March 2003. Approval for the trial was obtained from each center's institutional review board, and all participants provided written informed consent.
Participants were randomly assigned to a fixed combination of perindopril and indapamide (2 mg/0.625 mg for the first 3 months and 4 mg/1.25 mg thereafter) or matching placebo, and to either an intensive glucose control strategy (target HbA 1c #6.5%) or a standard glucose control strategy based on local guidelines.
Primary Analysis
In our primary analysis, we only included patients in the intensive glucose treatment group because our study protocol made it unlikely that we could reliably estimate glucose variability in the standard glucose treatment group, in which few measurements were taken (HbA 1c was only measured at 6, 12, and 24 months during the first 2 years of followup, and glucose was first measured at 24 months). After excluding 452 patients who experienced study outcomes of macro-and microvascular events or death during the first 24 months and 720 with missing values of HbA 1c and/or fasting glucose (morning), 4,399 patients were included in the primary analysis (Fig. 1) .
Glycemic Variability Assessment
Fasting samples for glucose assay and HbA 1c were taken at baseline, at 3, 6, 12, 18, and 24 months, and every 6 months thereafter in the intensive glucose treatment group. HbA 1c and fasting glucose were measured in local laboratories, and each HbA 1c measurement was standardized. Visit-to-visit variability (VVV) of HbA 1c or fasting glucose was evaluated using five measurements at 3, 6, 12, 18, and 24 months (Fig. 1) . Measurements during the first 2 months were excluded in order to eliminate the effect of rapid reduction in HbA 1c in this early period. The SD, coefficient of variation (CV), variation independent of mean (VIM), residual standard deviation (RSD), and average real variability (ARV) were used as indices of VVV (21, 22) . Mean and maximum values of HbA 1c during the 24-month evaluation period were also used in the present analyses.
Follow-up and Study Outcomes
In all analyses of outcomes, follow-up of patients ranged from their 24-month visit until they experienced events, death, or they completed the final visit at the end of the study. The primary outcome was a composite of major macrovascular and major microvascular events. Secondary outcomes were major macrovascular events, major microvascular events, and all-cause mortality. Major macrovascular events were defined as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Major microvascular events were defined as new or worsening nephropathy (development of macroalbuminuria, defined as a urinary albumin-creatinine ratio of .300 mg of albumin per milligram of creatinine, or doubling of serum creatinine level to at least 200 mmol/L, the need for renal replacement therapy, or death due to renal disease) or retinopathy (development of proliferative retinopathy, macular edema, or diabetes-related blindness or the use of retinal photocoagulation therapy).
Statistical Analysis
In order to test whether glycemic variability increased with time, the difference of the SD in glycemic variables between the first 2 years and thereafter was tested using a paired Student t test. Spearman correlation coefficients were estimated between measures of variability, maximum and mean HbA 1c or fasting glucose during the first 24 months. The effect of SD and maximum value of HbA 1c or fasting glucose were estimated by Cox proportional hazards models using groups defined by the deciles (the tenths). Adjustments were made for 1) age, sex, and randomized blood pressure lowering; 2) variables in model 1 plus region, duration of diabetes, baseline smoking status, baseline alcohol intake, systolic blood pressure, total cholesterol, log-transformed triglycerides, BMI, baseline use of oral glucose-lowering agents, and baseline use of insulin; and 3) variables in model 2 plus mean of HbA 1c or fasting glucose during the first 24 months. A linear trend was tested using a quantitative ordinal variable ranging from 1 to 10 to represent the tenths. Hazard ratios (HRs) and 95% CIs for each tenth relative to lowest category and for each 10-percentile point increase (trend) in variability were estimated in each model. Effects of variability (SD, CV, VIM, RSD, and ARV), maximum value, and average of HbA 1c or fasting glucose as continuous variables were also investigated using Cox proportional hazards models, and HRs per one SD increments were reported.
Sensitivity analyses were performed 1) using five measurements of HbA 1c or fasting glucose during 6-30 months to further eliminate the effect of early reduction in HbA 1c and 2) using the models including the imputation of missing values of HbA 1c or fasting glucose among 720 patients using multiple imputation (23) . The effects of SD of HbA 1c or fasting glucose were compared between subgroups defined by change in HbA 1c from 3 to 24 months within the range of 20.3 (23.3) to 0.3% (3.3 mmol/mol) or larger. Sensitivity analyses in the standard glucose treatment group were also performed using three measurements at 6, 12, and 24 months (Supplementary Data). Finally, in order to assess the effect of randomized treatment, the SD of HbA 1c was evaluated from three measurements at 6, 12, and 24 months and compared between the intensive and standard glucose treatment groups. The heterogeneity between subgroups was tested by adding an interaction term. All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC). A two-sided P , 0.05 was considered to be statistically significant.
RESULTS
Patient Characteristics and Glycemic Variability
Patient characteristics and visit-to-visit glycemic variability are summarized in Table 1 . The patients in the intensive glucose treatment group excluded from the analysis included a group of 452 who experienced events in the first 24 months and was thus a high risk subset. However, the baseline characteristics of patients included in the analyses were similar to those for the total ADVANCE population. Mean age was 65.5 years, 42.6% were female, and 31.9% were recruited in Asia. Maximum of HbA 1c or fasting glucose was strongly correlated with mean HbA 1c or fasting glucose (r . 0.90 for maximum), whereas indicators of VVV had modest to little correlation with mean HbA 1c or fasting glucose during 3-24 months (r = 0.30-0.60 for SD, CV, RSD, and ARV; ,0.15 for VIM) (Supplementary Table 1 ).
The mean SD of HbA 1c or fasting glucose for the intensive group was greater when estimated using five measurements rather than three (0.61 [6.7] Among 4,399 patients in the intensive glucose treatment group, there were 234 patients with major macrovascular events, 309 with major microvascular events, and 211 with deaths (43.1% for cardiovascular disease; 34.1% for cancer) during a median follow-up of 3.0 years (maximum 4.1 years) after completion of the 24-month visit. There were significant linear associations of SD of HbA 1c with combined macro-and microvascular events (P = 0.01 for trend), major macrovascular events (P = 0.02 for trend), and all-cause mortality (P , 0.001 for trend) even after adjusting for mean HbA 1c during the first 24 months and other confounding factors. SD of fasting glucose, adjusted for mean fasting glucose during the first 24 months and other factors, was also continuously associated with combined macro-and microvascular events (P , 0.001 for trend), major macrovascular events (P , 0.001 for trend), and major microvascular events (P = 0.005 for trend) (Fig. 2) . These associations between SD of HbA 1c or fasting glucose and all outcomes were broadly similar for measurements during 6-30 months ( Supplementary Fig. 1 ), and when missing values were imputed in the models (Supplementary Fig. 2 ). There was no heterogeneity in the effects of SD of HbA 1c or fasting glucose in subgroups defined by change in HbA 1c from 3 to 24 months within the range of 20.3 (23.3) to 0.3% (3.3 mmol/mol) or larger (all P for heterogeneity .0.25 for any of four outcomes) (Supplementary Table  2 ). Similar results were obtained when different indicators of variability in HbA 1c or fasting glucose were used as continuous variables (Supplementary  Tables 3 and 4) .
There were no clear associations between maximum HbA 1c among five measurements and any of the four outcomes (Fig. 3) . In contrast, maximum fasting glucose among five measurements had significant associations with combined macro-and microvascular events (P , 0.001 for trend), major macrovascular events (P = 0.01 for trend), and major microvascular events (P = 0.007 for trend) (Fig. 3) . These associations between maximum HbA 1c or fasting glucose and all outcomes were broadly similar for measurements during 6-30 months (Supplementary Fig. 3 ) and when missing values were imputed in the models ( Supplementary Fig. 4 ). Fig. 5 ).
CONCLUSIONS
This is the first large-scale study to report the effects of VVV in both HbA 1c and fasting glucose on a variety of outcomes in type 2 diabetes, including macrovascular events. The present analyses revealed that VVV in HbA 1c as well as that in fasting glucose predicted future development of macrovascular events, microvascular events, and all-cause deaths independent of cardiovascular risk factors, including mean HbA 1c or fasting glucose, and study treatments.
We have also shown that maximum value of fasting glucose was significantly associated with macrovascular and microvascular events. Both VVV and maximum of fasting glucose were stronger predictors than those of HbA 1c in that the HRs per decile increase were greater for both than those for HbA 1c . Several medium-sized observational studies have reported positive associations between VVV in HbA 1c and development or progression of microalbuminuria in type 2 diabetes (8-10), but we are unaware of the results for other types of outcomes. In the present analyses of ADVANCE, the association between SD of HbA 1c and microvascular events did not reach statistical significance (P = 0.06 for trend) although this is the largest study of type 2 diabetes to date. Instead, there were clear associations of SD of HbA 1c with macrovascular events and all-cause mortality.
The outcomes studied in previous observational studies that assessed the effects of VVV in fasting glucose in patients with type 2 diabetes were retinopathy and mortality only (4) (5) (6) (7) 24) . Most of those studies that investigated the risk of retinopathy reported positive associations (4, 6, 7) . An Italian population-based prospective cohort study also demonstrated a positive association between VVV in fasting glucose and all-cause mortality (24). In the current study, VVV in fasting glucose during the first 2 years was significantly associated with elevated risk of microvascular events and marginally with increased mortality (P = 0.07 for trend). The present results confirmed the findings of the previous observational studies and expanded the current evidence to incident macrovascular events.
Several mechanisms may be involved in the association between visit-to-visit glycemic variability and outcomes. First, glucose fluctuation has been shown to cause overproduction of superoxide (25, 26) . The oxidative stress generation is a key factor of atherosclerosis (27, 28) . Second, glycemic fluctuation has also been shown to cause an increase in inflammatory cytokines and monocyte and macrophage adhesion to endothelial cells (28), which are involved in the progression of atherosclerosis. Third, transient hyperglycemia causes longlasting epigenetic changes (29) , which may promote systemic inflammation. Additionally, glucose fluctuation has also been shown to cause loss of pancreatic b-cells due to increased apoptotic cell death (30) . The loss of pancreatic b-cells may result in deterioration of glycemic control (31) and subsequent progression of vascular complications or poor prognosis.
The strength of our study includes the large sample size and the rigorous evaluation of glycemic parameters and adjudication of major outcomes including macrovascular events. A limitation is possible selection bias due to exclusion of patients who experienced events during the first 24 months and those with missing values. However, baseline characteristics of patients included in the analyses were almost identical to those of the ADVANCE population (19) , and the sensitivity analyses including imputation of missing values for visit-to-visit glycemic variability provided similar results. Second, SD may be overestimated among the patients who experienced continued improvement in blood glucose during the evaluation period from 3 to 24 months. However, sensitivity analyses using RSD, which is an indicator of variability completely independent of changes over time, showed comparable findings, suggesting that this limitation is not likely to invalidate the findings of the present analysis. Third, we are unable to provide the accuracy of the particular assays used in the individual centers to measure HbA 1c and fasting glucose. Fourth, the possibility of residual confounding by unmeasured or unknown risk factors remains. Fifth, since the current study is observational, clinical trials investigating the favorable effects of reducing glycemic variability are needed to elucidate any direct causality. Last, the effect of visit-to-visit glycemic variability could not be reliably explored in the standard glucose treatment group because measurements were few. However, broadly similar results were obtained in the sensitivity analyses using three measurements in both randomized groups.
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